Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company’s NeuVax™ (nelipepimut-S) and GALE-301 and GALE-302 clinical programs will be presented at two upcoming medical conferences. Details of the presentations are as follows:

Conference: Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting
Poster #: 166
Abstract #: 156 – the abstract will be available on November will be published in the Journal for ImmunoTherapy of Cancer on Wednesday, November 4, 2015.
Title: Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39′) to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
Date: Friday, November 6, 2015
Time: 6:15 p.m. to 7:30 p.m. Eastern time
Location: Prince George’s Exhibition Hall at the Gaylord National Hotel & Convention Center in National Harbor, Maryland

GALE-301 (E39) and GALE-302 (E39′ – variant of E39; previously named J65) are folate binding protein (FB) peptides targeting FBP expressing tumors. The data to be presented at SITC is from a single-center, randomized, single-blinded, three-arm Phase 1b study of GALE-301 and GALE-302 in patients with breast or ovarian cancer diagnosis who have been treated by standard of care and are without evidence of disease. The primary endpoint of the trial is immunological and designed to determine which of the three primary vaccination sequence strategies maximizes long-term specific immunity defined as E39-specific cytotoxic T lymphocytes (CTLs) six months following completion of the primary vaccination series.

Conference: 33rd Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Poster #: 309
Title: NeuVax™ (nelipepimut-S) for the prevention of recurrence in HER2-expressing node positive breast cancer patients
Date:  Wednesday, November 4, 2015
Time:  6:00 p.m. to 7:00 p.m. Eastern time
Location:  Crown Plaza Hotel, New York, NY

In 2014, it is estimated there are 14.5 million cancer survivors in the United States. By 2024, it is projected there will be 19 million cancer survivors (DeSantis CE et al., 2014). In breast cancer patients, 50-60% who are HER2 IHC 1+/2+ or FISH < 2.0 achieve a response with current standard of care (SOC), but have no treatment options to maintain disease-free status. NeuVax is being studied to prevent breast cancer recurrence in these women in the adjuvant setting and maintain patients’ “survivor” status as a single agent in node positive as well as in combination with Herceptin®in node positive and triple negative disease (IHC 1+/2+) as well as high risk node positive and triple negative (IHC3+). (Original Source)

Shares of Galena Biopharma closed yesterday at $1.65. GALE has a 1-year high of $2.39 and a 1-year low of $1.10. The stock’s 50-day moving average is $1.70 and its 200-day moving average is $1.61.

On the ratings front, Galena has been the subject of a number of recent research reports. In a report issued on September 30, FBR analyst Vernon Bernardino maintained a Buy rating on GALE, with a price target of $5, which implies an upside of 203.0% from current levels. Separately, on September 28, Roth Capital’s Joseph Pantginis maintained a Buy rating on the stock and has a price target of $8.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Joseph Pantginis have a total average return of -18.5% and -6.1% respectively. Bernardino has a success rate of 25.0% and is ranked #3768 out of 3795 analysts, while Pantginis has a success rate of 33.7% and is ranked #3752.

The street is mostly Bullish on GALE stock. Out of 4 analysts who cover the stock, 3 suggest a Buy rating and one recommends to Sell the stock.

Galena Biopharma Inc, is a biopharmaceutical company focused on developing and commercializing targeted oncology therapeutics that address medical needs across the full spectrum of cancer care.